Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02750319 · ClinicalTrials.gov registry record · Phase 3

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

A Phase 3 study of Thoracic Surgery and Atrial Fibrillation in High Risk Patients, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 3
Development phase
184
Enrollment target
9
Study locations

NCT02750319: Active Phase 3 study of Thoracic Surgery and Atrial Fibrillation in High Risk Patients, sponsored by Memorial Sloan Kettering Cancer Center.

NCT02750319 is a Phase 3 study of Thoracic Surgery and Atrial Fibrillation in High Risk Patients that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 184 participants, above the 142-participant average among 5 other Thoracic Surgery trials with a reported enrollment target (30% higher). The trial reports 9 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02750319, a Phase 3 study of Thoracic Surgery and Atrial Fibrillation in High Risk Patients, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
184 participants
Enrollment target
9
Study locations

Study Summary

This trial will be comparing the combination of amiodarone and NAC (n=122) to amiodarone alone and NAC matched placebo (n=122) to determine the rates with which sustained (lasting \>30 seconds) or clinically significant POAF is reduced in high risk patients within 7 days after major thoracic surgery.

Interventions

  • DRUG Placebo
  • DRUG N-Acetylcysteine
  • DRUG Amiodarone

Study Locations (9)

New York

  • Memorial Sloan Kettering Commack (Consent only) - Commack
  • Memorial Sloan Kettering Westchester (Consent only) - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Rockville Centre (Consent only) - Rockville Centre
  • Memorial Sloan Kettering Nassau (Consent only) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Consent only) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent only) - Middletown
  • Memorial Sloan Kettering Bergen (Consent only) - Montvale

Missouri

  • University of Washington School of Medicine in St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2016-04
Est. Completion 2026-04
Phase Phase 3

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT02750319

The ClinicalTrials.gov registry entry for NCT02750319 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 142-participant average among 5 other Thoracic Surgery trials with a reported enrollment target (30% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Thoracic Surgery appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02750319 reports 9 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Missouri.

Frequently Asked Questions

What is clinical trial NCT02750319 about?

NCT02750319 is a clinical study titled "Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery". This trial will be comparing the combination of amiodarone and NAC (n=122) to amiodarone alone and NAC matched placebo (n=122) to determine the rates with which sustained (lasting \>30 seconds) or clinically significant POAF is reduced in high risk patients within 7 days after major thoracic surgery...

What is the current status of trial NCT02750319?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2016-04. Estimated completion is 2026-04.

What conditions does trial NCT02750319 study?

This clinical trial studies the following conditions: Thoracic Surgery, Atrial Fibrillation in High Risk Patients.

What interventions are being tested in trial NCT02750319?

The interventions under investigation include: Placebo (DRUG), N-Acetylcysteine (DRUG), Amiodarone (DRUG).

Who is sponsoring clinical trial NCT02750319?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02750319 being conducted?

This trial has 9 study locations across Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thoracic Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.